IL275577A - Antibodies and their variants against PD-L1 - Google Patents

Antibodies and their variants against PD-L1

Info

Publication number
IL275577A
IL275577A IL275577A IL27557720A IL275577A IL 275577 A IL275577 A IL 275577A IL 275577 A IL275577 A IL 275577A IL 27557720 A IL27557720 A IL 27557720A IL 275577 A IL275577 A IL 275577A
Authority
IL
Israel
Prior art keywords
antibodies
variants
Prior art date
Application number
IL275577A
Other languages
English (en)
Hebrew (he)
Original Assignee
Nanjing Legend Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotech Co Ltd filed Critical Nanjing Legend Biotech Co Ltd
Publication of IL275577A publication Critical patent/IL275577A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL275577A 2017-12-28 2020-06-22 Antibodies and their variants against PD-L1 IL275577A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017119505 2017-12-28
PCT/CN2018/124925 WO2019129211A1 (en) 2017-12-28 2018-12-28 Antibodies and variants thereof against pd-l1

Publications (1)

Publication Number Publication Date
IL275577A true IL275577A (en) 2020-08-31

Family

ID=67066642

Family Applications (1)

Application Number Title Priority Date Filing Date
IL275577A IL275577A (en) 2017-12-28 2020-06-22 Antibodies and their variants against PD-L1

Country Status (11)

Country Link
US (1) US12168688B2 (enExample)
EP (1) EP3732203A4 (enExample)
JP (1) JP7383617B2 (enExample)
KR (1) KR102845020B1 (enExample)
CN (1) CN111542543B (enExample)
AU (1) AU2018396964C1 (enExample)
CA (1) CA3078849A1 (enExample)
IL (1) IL275577A (enExample)
SG (1) SG11202005273XA (enExample)
TW (1) TW201930350A (enExample)
WO (1) WO2019129211A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202005273XA (en) 2017-12-28 2020-07-29 Nanjing Legend Biotech Co Ltd Antibodies and variants thereof against pd-l1
TW202020159A (zh) 2018-11-16 2020-06-01 大陸商南京金斯瑞生物科技有限公司 人源化抗人pd-l1單克隆抗體及其製備方法和用途
CN114008080B (zh) * 2019-06-12 2023-06-09 南京金斯瑞生物科技有限公司 抗pd-l1/抗lag-3多抗原结合蛋白及其使用方法
US20220332827A1 (en) * 2019-08-23 2022-10-20 WuXi Biologics Ireland Limited Humanized antibodies against pd-l1
JP2022521958A (ja) 2019-08-29 2022-04-13 榮昌生物制薬（烟台）股▲フン▼有限公司 抗ｐｄ－ｌ１抗体及びその応用
US11877018B2 (en) 2019-11-15 2024-01-16 Korea Advanced Institute Of Science And Technology Live video ingest system and method
CN115135675A (zh) * 2020-02-18 2022-09-30 南京金斯瑞生物科技有限公司 融合蛋白及其用途
WO2022031695A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Pd-l1 binding agents and uses thereof
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
WO2023060278A2 (en) * 2021-10-08 2023-04-13 Tiberias Technology (Hk) Limited Tibtech methods and compositions for detecting cdh17
KR102534281B1 (ko) * 2022-09-02 2023-05-30 한국생명공학연구원 신규한 항-pd-l1 키메릭 항원 수용체 및 이를 발현하는 면역세포
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ，インコーポレイテッド 癌マーカー用生物合成結合蛋白質
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
JPWO2003085119A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT CONTAINING ANTIBODY COMPOSITION
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003301882A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk COMPOSITION OF CONDENSED PROTEINS
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
JP4653109B2 (ja) 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
KR101481843B1 (ko) 2006-01-25 2015-01-12 에라스무스 유니버시티 메디컬 센터 로테르담 형질전환 동물 내에서의 중쇄만의 항체의 생성
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
CN101104640A (zh) * 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
TWI434854B (zh) * 2007-11-13 2014-04-21 Evec Inc 結合ｈＧＭ－ＣＳＦ的單株抗體以及包含其之醫學組成物
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
MX2011003195A (es) * 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
CN104131035A (zh) 2009-12-10 2014-11-05 瑞泽恩制药公司 生产重链抗体的小鼠
RS61033B1 (sr) * 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
US10435470B2 (en) 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
CN105777906B (zh) 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
MX2018005720A (es) * 2015-11-17 2018-11-09 Suzhou Suncadia Biopharmaceuticals Co Ltd Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
MA43260A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
JP6432121B2 (ja) * 2016-03-04 2018-12-05 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド Ｐｄｌ−１抗体、その医薬組成物及びその使用
JP7080213B2 (ja) 2016-03-23 2022-06-03 スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド 新規抗ｐｄ－ｌ１抗体
SG10202109691UA (en) * 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
IL321475A (en) 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
CN105968200B (zh) 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
CN107488229B (zh) * 2016-06-13 2020-11-17 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
MY190771A (en) * 2016-06-13 2022-05-12 I Mab Biopharma Us Ltd Anti-pd-l1 antibodies and uses thereof
US10787518B2 (en) * 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CN108239149B (zh) * 2016-12-25 2021-03-05 南京传奇生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
DK3606955T3 (da) * 2017-04-05 2025-01-13 Hoffmann La Roche Bispecifikke antistoffer, der specifikt binder sig til PD1 og LAG3
SG11202005273XA (en) 2017-12-28 2020-07-29 Nanjing Legend Biotech Co Ltd Antibodies and variants thereof against pd-l1

Also Published As

Publication number Publication date
AU2018396964B2 (en) 2024-07-04
KR20200104886A (ko) 2020-09-04
CN111542543B (zh) 2023-12-22
JP7383617B2 (ja) 2023-11-20
TW201930350A (zh) 2019-08-01
JP2021508707A (ja) 2021-03-11
EP3732203A1 (en) 2020-11-04
US20220135687A1 (en) 2022-05-05
AU2018396964A1 (en) 2020-08-06
EP3732203A4 (en) 2021-12-15
KR102845020B1 (ko) 2025-08-12
US12168688B2 (en) 2024-12-17
CN111542543A (zh) 2020-08-14
SG11202005273XA (en) 2020-07-29
WO2019129211A1 (en) 2019-07-04
AU2018396964C1 (en) 2024-10-03
CA3078849A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
IL324062A (en) Anti-CD73 antibodies and their uses
IL274438A (en) Single-region antibodies against PD-L1 and their variants
ZA202105676B (en) Anti-trem2 antibodies and related methods
ZA202102905B (en) Anti-galectin-9 antibodies and uses thereof
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and their uses
IL275575A (en) Single site antibodies and their variants against TIGIT
IL272218A (en) ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS
IL275737A (en) Variant antibodies against TIGIT
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL268206A (en) Antibodies directed against bcma and their use
IL275577A (en) Antibodies and their variants against PD-L1
IL264970A (en) Anti-tim-3 antibodies and their use
SMT202400323T1 (it) Anticorpi contro pd-l1
IL269134A (en) Antibodies against PAR2 and their use
IL273157A (en) Antibodies specific to AXL and their uses
HUE055621T2 (hu) Il-33-ellenes antitestek és alkalmazásaik
IL272476A (en) Anti-Apelin antibodies and their uses
IL274202A (en) Antibodies against Glyco-Moc1 and uses thereof
GB201712032D0 (en) Antibodies and uses thereof
SG11202003585VA (en) Anti-vista antibody and use thereof
ZA201906248B (en) Anti-ceacam1 antibody and use thereof
HK40038966A (en) Antibodies and variants thereof against pd-l1
HK40027259A (en) Single-domain antibodies and variants thereof against pd-l1